Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics - Open|April 19, 2021
Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical TrialYoav Golan, Yuexin Tang, Shahrul Mt-Isa, et al.
Human Vaccines & Immunotherapeutics|April 12, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trialVu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, et al.
The Lancet. Haematology|December 24, 2023
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialDomenico Russo, Michael Schmitt, Sylvain Pilorge, et al.
Clinical Pharmacology and Therapeutics|October 21, 2021
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation RecipientsMarita Prohn, Carolyn R Cho, Anders Viberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 1, 2025
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell TransplantGenovefa A Papanicolaou, Sanjeet S Dadwal, Ella J Ariza-Heredia, et al.
The Pediatric Infectious Disease Journal|January 19, 2024
Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation RecipientsAndreas H Groll, Johannes H Schulte, Ali Bülent Antmen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2019
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell TransplantationPer Ljungman, Michael Schmitt, Francisco M Marty, et al.
Antimicrobial Agents and Chemotherapy|August 18, 2025
Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b studyAndreas H Groll, Lara Danziger-Isakov, Aharon Gefen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2024
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections ForumPer Ljungman, Roy F Chemaly, Fareed Khawaya, et al.
Eclinicalmedicine|July 9, 2020
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countriesSusanne K Kjaer, Mari Nygård, Karin Sundström, et al.
Pageof 2